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Palliative treatment of metastatic bone pain with radiopharmaceuticals: a 
perspective beyond Strontium-89 and Samarium-153 
ABSTRACT 
Purpose: The present review article aims to provide an overview of the available radionuclides for palliative 
treatment of bone metastases beyond 89Sr and 153Sm. In addition, it aims to review and summarize the 
clinical outcomes associated with the palliative treatment of bone metastases using different 
radiopharmaceuticals. Materials and Methods: A literature search was conducted on Science Direct and 
PubMed databases (1990 - 2015). The following search terms were combined in order to obtain relevant 
results: “bone”, “metastases”, “palliative”, “care”, “therapy”, “treatment”, “radiotherapy”, “review”, 
“radiopharmaceutical”, “phosphorus-32”, “strontium-89”, “yttrium-90”, “tin-117m”, “samarium-153”, 
“holmium-166”, “thulium-170”, “lutetium-177”, “rhenium-186”, “rhenium-188” and “radium-223”. Studies 
were included if they provided information regarding the clinical outcomes. Results and Conclusions: A 
comparative analysis of the measured therapeutic response of different radiopharmaceuticals, based on 
previously published data, suggests that there is a lack of substantial differences in palliative efficacy 
among radiopharmaceuticals. However, when the comparative analysis adds factors such as patient’s 
life expectancy, radionuclides’ physical characteristics (e.g. tissue penetration range and half-life) and 
health economics to guide the rational selection of a radiopharmaceutical for palliative treatment of 
bone metastases, 177Lu and 188Re-labeled radiopharmaceuticals appear to be the most suitable 
radiopharmaceuticals for treatment of small and medium/large size bone lesions, respectively. 
 
Key words: Radiopharmaceutical; Bone metastases; Systematic review; Alpha particles; Beta particles; Auger 
electrons.  
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I. INTRODUCTION 
Bone metastases are a common and severe complication in patients diagnosed with primary 
tumours. It develops in up to 70% of patients diagnosed with prostate cancer and breast cancer and in 
up to 30% of those with cancers of the lung, bladder and thyroid. The major complications associated 
with bone involvement are severe pain, spinal cord compression, hypercalcemia and pathological 
fracture, all of which compromise the patient’s quality of life. Several therapeutic approaches 
targeting bone metastases and its associated effects are available, including the use of analgesics, 
chemotherapy, external beam radiotherapy and radionuclide systemic therapy. The latter, systemic 
palliative targeted therapy with suitable radiopharmaceuticals, has emerged as a particularly appealing 
and efficient treatment modality for patients with multiple skeletal metastases (Maini et al., 2003; 
Pandit-Taskar et al., 2014; Pillai et al., 2003; Silberstein and Drive, 1996). 
Radionuclide therapy is characterized by the reasonably selective delivery of therapeutic 
doses of radiation to systemically dispersed target tissues, with generally limited toxicity and few 
long-term side-effects (Unak, 2002). The basis of successful radionuclide therapy relies on a high 
concentration and adequate retention of the radiopharmaceutical at the tumour site. The concept of 
targeted therapy introduced in 1898 by Paul Ehrlich, i.e. the “magic bullet” concept, has paved the 
way for the development of successful approaches for treatment of different diseases based on 
radiopharmaceutical systemic administration (Ehrlich and Herter, 1904; Vial and Callahan, 1957). A 
notable example is the treatment of hyperthyroidism and thyroid cancer using Na131I. Since then, a 
wide variety of radiolabeled agents has been used clinically for treatment of different types of 
diseases, but only a limited number of these preparations have obtained regulatory approval for 
routine clinical use in patients and are commercially available (Das and Pillai, 2013). Examples of 
diseases that have been treated by nuclear medicine therapy are: thyroid carcinoma, hyperthyroidism, 
metastatic bone pain, polycythemia rubra vera, neuroendocrine tumors (NETs), liver metastases, 
lymphoma and neuroblastoma. Among these, treatment of thyroid cancer with 131I is the most widely 
used radionuclide-targeted therapy. The second most widely used application is for bone pain 
palliation in the context of metastatic cancer (Das and Pillai, 2013). 
There are essentially three main types of particulate radiations that are of interest for 
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palliative treatment of bone metastasis using radiopharmaceuticals: beta minus (β-) particles, alpha (α) 
particles and Auger electrons. Traditionally, tumor-targeted radiotherapy has used β- emitting 
radionuclides. However, high-energy β- particles, with a range of several millimeters in tissues, can 
irradiate cells nearby the targeted tumor. Conversely, α particles (typical penetration range of less 
than 100 µm) (Harrison et al., 2013) and Auger electrons (penetration range of several nanometers to 
micrometers) have shorter penetration ranges and higher linear energy transfer (LET) (Unak, 2002). 
Radiopharmaceuticals deposition sites in the cell is another important factor to consider during 
palliative treatment of bone metastases using radiopharmaceuticals. For instance, if deposition occurs 
in the cell nucleus, an Auger electron emitter radionuclide may be adequate for cell killing, while in 
the case of cell surface deposition, β- or α particle-emitting radionuclides may be preferable. 
Therefore, the design of the carrier molecule to be labelled with the radionuclide should consider the 
physical properties of the radionuclide to be used. For short-range particles, such as Auger electrons, 
this means the carrier molecule should be able to cross the cellular membrane either by passive 
diffusion or via specific carrier mediated process, in order to reach the cell nucleus and to associate 
with the deoxyribonucleic acid (DNA) complex for a time corresponding to the radionuclide half-life 
(Unak, 2002). Cell and tissue studies have shown that once Auger electron emitters are introduced 
into the cell’s cytoplasm, they will present similar effects to those induced by low LET radiations, but 
when they are introduced close to DNA, the survival curves will be similar to those obtained with 
high LET α particles (Sastry, 1992). Dosimetric calculations have also supported these observations. 
For example, the decay of 125I has been shown to lead to the deposition of a very high dose (≈109 
cGy/decaying atom) in the immediate vicinity (≈2 nm3) of the decay site and a sharp and significant 
drop in the energy deposited (from ≈109 to ≈106 cGy) as a function of increasing distance (few 
nanometres) from the decaying 125I atom (Kassis, 2011). For example, when 125I is localized within 
the cytoplasm, the survival curve is of the low LET type and the number of decays needed to reduce 
survival is ≈80 times that of DNA-incorporated 125I (Kassis, 2011). 
In recent years, several reports have been published describing the use of multiple 
radionuclides in the context of palliative treatment of bone metastases. Radionuclides investigated for 
this application included: phosphorus-32 (32P), strontium-89 (89Sr), yttrium-90 (90Y), tin-117m 
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(117mSn), samarium-153 (153Sm), holmium-166 (166Ho), thulium-170 (170Tm), lutetium-177 (177Lu), 
rhenium-186 (186Re), rhenium-188 (188Re) and radium-223 (223Ra) (Abbasi, 2012, 2011; Argyrou et 
al., 2013a; Bączyk, 2011; Bryan et al., 2009; Chakraborty et al., 2008; Daha et al., 2010; Das et al., 
2009; Harrison et al., 2013; Lewington, 2005; Máthé et al., 2010; Neves et al., 2005; Nilsson et al., 
2013b, 2007, 2005a, 2005b; Pandit-Taskar et al., 2014; Ramdahl et al., 2013; Sartor, 2004; Simón et 
al., 2012; Sivaprasad and Rajagopal, 2012; Tomblyn, 2012; Vigna et al., 2011; Volkert and Hoffman, 
1999; Wang et al., 2011). Despite the growing number of radionuclides investigated for treatment of 
bone metastases, the use of 89Sr and 153Sm still accounts for the bulk of radiopharmaceutical bone-
targeted therapeutics in the clinical context and the majority of the review articles available in the 
literature focus on those two radionuclides. The present review article has a two-fold aim: 1) to 
provide an overview of all available radionuclides for palliative treatment of bone metastases, 
including a description of the key characteristics of such radionuclides; and 2) to describe the clinical 
outcomes associated with the palliative treatment of bone metastases with different 
radiopharmaceuticals. The ultimate objective of this review is to provide a state-of-science report on 
radionuclides and radiopharmaceuticals currently in clinical use or under research for the palliative 
treatment of bone metastases, and to propose an approach for the rational evaluation and selection of 
radiopharmaceuticals for palliative treatment of bone metastases. 
 
II. PHYSICAL PROPERTIES AND PRODUCTION METHODS OF RADIONUCLIDES FOR 
BONE PAIN PALLIATION 
Table I presents the summary of the key physical properties of these radionuclides and the 
next sections provide details on the properties of each radionuclide.  
 
< Insert Table I around here > 
 
II.A. PHOSPHORUS-32  
Phosphorus-32 (32P) was the first radioisotope to be evaluated for palliative treatment of bone 
metastases, and its first clinical use dates back to 1941 (Bouchet et al., 2000; Lawrence et al., 1947; 
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Nair, 1999; Silberstein et al., 1992). 32P (t1/2=14.26 d, E(max)=1.71 MeV, E(mean)=0.696 MeV) can be 
prepared by neutron activation of natural phosphorus (31P(n,γ) 32P, 100% abundance, σ = 0.172 
barns) or sulfur (32S(n,p) 32P, 95.02% and σ = 0.54 barns). The specific activity of 32P formed in the 
former reaction is extremely low; and the cross-section of 32S(n,p) 32P is only 0.54 barns, which 
means that several hundred grams of sulfur need to be irradiated, in order to have few hundred 
milliCuries of 32P. The specific activity of 32P can also be further reduced due to the introduction of 
31P impurities during the radiochemical processing. Moreover, as a result of the low production 
cross-section, large irradiation volumes are often required (Bé et al., 2008; Vimalnath et al., 2013). 
This radionuclide can also be produced by direct neutron capture using elemental phosphorus as the 
target, which is a simpler and more cost-effective method. However, 32P produced via this route is of 
very low specific activity (Das and Pillai, 2013).  
 
II.B. STRONTIUM-89 
Strontium-89 (89Sr) (t1/2=50.5 d, E(max)=1.49 MeV, E(mean)=0.585 MeV, Eγ=909 keV (0.1%)) is 
a pure β- emitter (Ota et al., 2011). This radionuclide is usually produced via 88Sr(n,γ)89Sr reaction in 
very high flux reactors. Despite the natural isotopic abundance of 88Sr being very high (82.3%), an 
extremely enriched target is needed to avoid the contamination of 89Sr with 85Sr. The significantly 
low thermal neutron capture cross-section (0.058 barns) of 88Sr(n,γ) 89Sr reaction results in low yield 
of production even when the irradiation is done in very high flux reactor. Alternatively, 89Sr can be 
produced using 89Y(n,p) 89Sr nuclear reaction, but the cross-section of this reaction with thermal 
neutrons is even lower than the 88Sr(n,γ)89Sr reaction (0.0002044 versus 0.058 barns). Consequently, 
the costs of 89Sr-based bone pain palliation therapies are expected to remain high (Das and Pillai, 
2013). In addition to the high production costs and low reactions yields, the specific activity of the 
formed 89Sr is very low when obtained by direct production. 
 
II.C. YTTRIUM-90 
90Y (t1/2=2.67 d, , E(max)=2.27 MeV, E(mean)=0.267 MeV, no γ emission) (Bé et al., 2008) is a 
pure β- emitter which has well-established applications in targeted radiotherapy. A favorable route 
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for obtaining large quantities of 90Y is to employ a 90Sr/90Y radionuclide generator. Alternatively, 
90Y may be obtained by direct neutron irradiation of a natural yttrium target, 89Y(n,γ)90Y.(Das and 
Pillai, 2013)  
 
II.D. TIN-117m 
Tin-117m (117mSn) emits low energy conversion electrons with a very high LET (t1/2=13.6 d, 
conversion electron’s energies of 127 (62%), 129 (12%) and 152 (26%) keV, Eγ=159 keV (86%)) 
(Bé et al., 2008). 117mSn is produced either by neutron activation using enriched 116Sn target, via the 
116Sn(n,γ)117mSn nuclear reaction or by inelastic neutron scattering on enriched 117Sn, 
117Sn(n,n’,γ)117mSn (Das and Pillai, 2013; Maslov et al., 2011). However, owing to the poor cross-
section of both these reactions and the need for a very high flux reactor and highly enriched targets 
that are essential to produce sufficient quantities of 117mSn, large-scale production of this 
radionuclide is not practical. Moreover, the low specific activity of the produced 117mSn can be a 
limiting factor for radiolabelling of target compounds (Srivastava, 2013). Additional accelerator 
based production routes have been investigated to produce no carrier added (nca) 117mSn, using 3He 
particle-induced reactions on 116Cd and 115In (Maslov et al., 2011; Srivastava, 2013). However, these 
reactions could provide only low yield. 
The 117mSn electrons have short penetration range and, hence, low bone marrow radiation 
dose. Therefore, radiotherapy agents labelled with 177mSn would have low myelotoxicity (Das and 
Pillai, 2013). Moreover, the gamma emission of 117mSn is in the ideal range for scintigraphic 
interrogation, thus allowing for acquisition of images for dosimetry estimates, as well as, for 
treatment response monitoring. 
 
II.E. SAMARIUM-153 
Presently, one of the most commonly used radionuclides for palliative treatment of bone 
metastases in routine clinical practice is Samarium-153 (153Sm) (t1/2=1.93 d, E(max)=0.81 MeV, 
E(mean)=0.225 MeV, Eγ=103 keV (28%)) (Bé et al., 2008). 153Sm can be produced from neutron 
capture of natural or isotopically enriched 153Sm as Sm2O3 in a nuclear reactor. Owing to the large 
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thermal neutron capture cross-section of 152Sm(n,γ) 153Sm reaction (206 barns), 153Sm can be 
produced in large quantities and with high specific activity (Neves et al., 2002). A disadvantage of 
153Sm is its relatively short half-life, which restricts the transport of the radiopharmaceutical to 
distant sites far from the production site of the radioisotope (Das and Pillai, 2013).  
 
II.F. HOLMIUM-166 
Holmium-166 (166Ho) is primarily a β- emitter (t1/2=1.12 d, E(max)=1.85 MeV, E(mean)=0.651 
MeV) with a maximum path length of 8.6 mm in soft tissue and 3.8 mm in bone. It has a complex 
energy spectrum for quantitative imaging, but the low abundance (7%) of 81 keV photons can be 
used for gamma-camera imaging (Breitz et al., 2006). 166Ho can be produced directly from neutron 
irradiation of 165Ho, but long-lived 166mHo is also produced, which might result in suboptimal 
dosimetry. The activation cross-section is 66 barns and hence relatively large quantities of 166Ho can 
be prepared with relatively high specific activity (135mCi/mg at a thermal neutron flux of 4x1013 
n.cm-2.s-1) for therapeutic applications (Zolghadri et al., 2013). No carrier added (nca) 166Ho can be 
produced from the generator system 166Dy-166Ho. 166Dy (T1/2 = 81 h) is prepared by double neutron 
capture of 164Dy; however, the production yields will only be moderate due to double neutron 
capture reaction. The specific activity of the 166Ho produced by direct neutron activation is adequate 
for several applications. Notwithstanding, due to its short half-life, the site to produce the 
radiopharmaceutical needs to have knowledge in radiochemistry, which would set limits. 
 
II.G. THULIUM-170 
Thulium-170 (170Tm) (t1/2=128.4 d, E(max)=0.968 MeV, E(mean)=0.323 MeV, Eγ=84 keV 
(3.3%)) decays to stable 170Yb by emission of β- particles. This radionuclide can be produced by a 
relatively easy route involving thermal neutron bombardment on natural Tm2O3 (169Tm) in medium 
flux research reactors with a relatively low specific activity (Das et al., 2009; Neves et al., 2005). 
Das et al. in 2009 proposed the use of 170Tm-labelled radiopharmaceuticals as a potential alternative 
to 89Sr-chloride for bone pain palliation, as it is readily available (Das et al., 2009). The long 
physical half-life of 170Tm (128.6 days) can also be an advantage for this radiopharmaceutical 
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distribution and storage compared with other radionuclides (Goyal and Antonarakis, 2012). On the 
other hand, the long half-life of 170Tm has an important disadvantage in terms of radioactive 
contamination and disposal of contaminated waste and possibly lower biological effectiveness due 
the relative low dose rate per unit of time. 
 
II.H. LUTETIUM-177 
Another promising radionuclide recently proposed for palliative treatment of bone metastases 
is Lutetium-177 (177Lu) (E(max)=0.49 MeV, E(mean)=0.149 MeV) due to its appealing physical 
characteristics, in particular, its half-life of 6.73 days, gamma ray emissions of 113keV (6.4%) and 
208 keV (10.4%) and tissue penetration of 1.8 mm (Das et al., 2009; Dash et al., 2015). A series of 
177Lu-labeled compounds have been brought to clinical trials stage. The most important advantage of 
177Lu is that it can be produced in large quantities, by employing either the neutron activation of 
Lu2O3 (carrier added (ca) form by direct high cross section, ≈2100 b) or through an enriched Yb2O3 
as the target material (Das and Pillai, 2013). Both reactor production routes can yield 177Lu for 
nuclear medicine applications. The direct production route is based on neutron irradiation of 176Lu, 
via 176Lu(n,γ)177Lu reaction, the specific activity values vary significantly depending upon the 
irradiation conditions (neutron flux, irradiation time, etc.). For direct irradiation of enriched 176Lu, a 
specific activity value >35 Ci/mg can be obtained at neutron flux >3x1013 n.cm-2.s-1 (Pillai et al., 
2015, 2003). The indirect 176Yb(n,γ)177Yb→177Lu production route requires chemical separation of 
177Lu from the 176Yb target atoms and the specific activity should be close to the theoretical value 
(110 Ci/mg) (Dash et al., 2015; Pillai et al., 2015).  
Lu-177 relatively long half-life can provide a logistical advantages when supplying to distant 
sites from the reactor production facility compared with other shorter lived radionuclides. This 
radionuclide has several advantages to be explored as a therapeutic radionuclide for bone pain 
palliation, including its lower β- particle energy. Among the β- particle emitters investigated thus far 
for bone pain palliation, 177Lu has the lowest tissue penetration range (1.8 mm). A common concern 
associated with the use of β- particle emitters is related to their large tissue penetration range of 
several millimeters, which can result in energy deposition in neighboring, non-targeted cells 
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(Jackson et al., 2013). The short tissue penetration range of 177Lu β- particles is placed in the lowest 
end of the β- particle emitter’s tissue penetration range, minimizing the negative “crossfire” effects 
often associated with β- particle emitters. In addition, 177Lu low β- particle energy and intermediate 
physical half-life of 6.73 days allow the deposition of an adequate tumor irradiation dose with a 
homogeneous distribution during the treatment follow-up (14 days) (Máthé et al., 2010). 
Additionally, lutetium exclusively exists in the +3 oxidation state, which provides the potential for 
radiolabeling a variety of molecular carriers, which include small molecules, peptides, proteins and 
antibodies for therapy. 
 
II.I. RHENIUM-186 AND RHENIUM-188 
In the late 1980s, 186Re (t1/2=3.8 d) was identified as a potential agent for palliative treatment 
of bone metastases and it is currently being used in phase III clinical trials (Goyal and Antonarakis, 
2012). 186Re is a combined β- and γ-emitter with a maximum β-emission of 1.07 keV and a 9% 
abundant γ-ray emission of 137 keV, which is suitable for gamma-camera imaging (Han et al., 
2002). This radionuclide can be produced either in a nuclear reactor or in a particle accelerator 
(cyclotron). The first method utilizes neutron capture of enriched 185Re, 185Re(n,γ)186Re. In the 
second method, the 186Re is obtained mainly via proton bombardment of natural tungsten 186W as a 
target (Argyrou et al., 2013b).  
The therapeutic potential of 188Re (t1/2=0.7 d, E(max)=2.12 MeV, Eγ=155 keV (15%)) has 
recently been considered and investigated (Bé et al., 2008). The availability of no carrier added 
188Re from the 188W/188Re generators makes the use of 188Re convenient. However, currently, there 
are only a few reactors in the world capable of production of sufficiently high specific activity 188W 
needed for the preparation of alumina-based commercial 188W/188Re generator (Argyrou et al., 
2013a; Das and Pillai, 2013). The short physical half-life and high dose rate are predicted to lead to 
rapid symptom response post therapy administration (Lewington, 2005; Knut Liepe et al., 2003).  
186Re and 188Re are two of the radionuclides that can be prepared in nuclear reactors with 
reasonably high specific activities by using enriched targets (Neves et al., 2002). Interestingly, the 
chemical properties of rhenium are similar to technetium as both these elements exist in group VIIb of 
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the periodic table (Kothari et al., 1999), which may provide for the opportunity to label the carrier 
molecule with either 186/188Re for target-radiotherapy or the vastly used imaging radionuclide, 
technetium-99m. However, though technetium and rhenium possess chemical analogy with each 
other, it is known that rhenium complexes are more difficult to prepare than technetium analogues. 
Rhenium complexes have a higher tendency to get reoxidized back to perrhenate than do the 
analogous technetium complexes (Kothari et al., 1999). This reoxidation and consequently, the 
presence of high radiochemical impurities in the final product, is one of the major hindrances in the 
development of rhenium radiopharmaceuticals.  
 
II.J. RADIUM-223 
Recently, a significant amount of work has been carried out using Radium-223 (223Ra), a 
promising therapeutic agent for palliative treatment of bone metastases, in order to take advantage of 
the low tissue penetration range associated with its emitted α particles. 223Ra α particle emission is 
an appealing strategy for the treatment of bone micrometastases, owing to the short tissue range 
penetration associated with these radioactive particles that can allow for a more circumscribed 
irradiation surface. Consequently, α emitters induce typically less hematologic toxicity for a 
given bone surface dose than β- emitters (Harrison et al., 2013; Nilsson et al., 2013b; Pandit-
Taskar et al., 2014). Furthermore, the high LET of α particles has been associated with greater 
biological effectiveness than β- particles (Harrison et al., 2013; Nilsson et al., 2013b; Pandit-
Taskar et al., 2014). 
Although 223Ra (t1/2=11.4 days) is formed naturally in trace amounts by the decay of uranium-
235, it is generally made artificially, via a generator from the parent 227Ac (t1/2=21.8 y) (Eriksen et 
al., 2012). 223Ra emits 4 α particles through its decay scheme with mean α energy of 5.7 MeV. 
Because of inherent bone-seeking properties, cationic 223Ra is a suitable radionuclide for the delivery 
of high-LET radiation to cancer cells and bone surfaces (Bé et al., 2011; Brechbiel, 2007; Eriksen et 
al., 2012). The α particles deposit 1500 times more energy per unit path length compared with β-
particles. This high mean energy deposition in tissues confers α radiation exquisite cytotoxicity 
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properties, which commonly manifests itself within the range of cell’s dimensions. Such high LET 
may allow for an accurately controlled therapeutic modality that can be targeted to selected 
malignant cells with negligible burden to normal tissues. 
 
III. BIODISTRIBUTION AND CLINICAL OUTCOMES OF DIFFERENT 
RADIOPHARMACEUTICALS FOR BONE PAIN PALLIATION 
Table II presents the summary of the biodistribution key features and clinical outcomes of 
different radiopharmaceuticals currently in use in the clinical setting or under investigation for the 
palliative treatment of bone metastases. Detail on the characteristics summarized for each 
radiopharmaceutical in Table II is provided in the next sections. 
 
< Insert Table II around here > 
 
III.A. 32P-ORTHOPHOSPHATE 
32P-orthophosphate is used for the management of bone pain palliation in skeletal metastasis, 
and it is reported to have similar efficacy as that of 89Sr-chloride (Das and Pillai, 2013). 32P-
orthophosphate has been administered orally or as a single intravenous injection of 185 to 444 MBq 
(5 to 12 mCi) (Silberstein, 2005). Following administration, 85% of the activity is incorporated into 
the bone hydroxyapatite, an uptake mechanism that was demonstrated by Lawrence et al. (Lawrence 
et al., 1939). 
The long path of 32P β- particles means that the bone marrow will receive a considerable 
amount of radiation. As a result, common adverse effects from administration of 32P-orthophosphate 
include bone marrow suppression, and there is evidence supporting for a higher degree of 
myelosuppression for this radionuclide compared with other radionuclides presented in Table I. 
Thus, poor hematological function is a contraindication to radiotherapy with 32P-orthophosphate 
(IAEA, 2007).  
 
The 32P-orthophosphate overall response rate ranges between 50% and 87% and the mean 
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reported duration of response is 5 months, with the longest responses reported of 17 months 
(Lewington, 2005; Silberstein, 2005). The tumor to non-tumor ratio is not very favorable, and the 
relief of pain is primarily because of its uptake into mineral bone rather than tumor uptake. In fact, 
in addition to the skeletal bone uptake, this radiopharmaceutical uptake is also high in rapidly 
dividing tissues, such as the intestinal wall and the red marrow (Srivastava, 2007). 
 
III.B. 89Sr-CHLORIDE 
Soluble strontium compounds behave like their calcium analogs, clearing rapidly from the 
blood and selectively localizing in the mineral bone. Uptake of strontium by bone occurs 
preferentially in sites of active osteogenesis and, thus primary bone tumors and areas of metastatic 
involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than 
surrounding normal bone. 
Strontium chloride (89SrCl2, commercial name Metastron, GE Healthcare) is used for 
providing palliative care to the patients suffering from bone pain due to skeletal metastasis (Das and 
Pillai, 2013). When injected intravenously, 89SrCl2 substitutes calcium in the bone hydroxyapatite. 
This radiopharmaceutical is excreted by both renal (80%) and fecal (20%) routes. Approximately 
30% to 35% of the radiopharmaceutical remains in the bone, with a 10-fold higher uptake for 
metastatic tumor compared to healthy bone (Goyal and Antonarakis, 2012; Silberstein, 2005). The 
usual dosage administered is either 148 MBq (4 mCi) or 1.48 MBq/kg (40 µCi/kg), where 
administration of larger doses of this radiopharmaceutical result in proportionally higher 
myelosuppression (Silberstein, 2005).   
Bone marrow toxicity is to be expected following the administration of the 
radiopharmaceutical, with reduction in white blood cells and platelets counts. Typically, platelets 
will be depressed by about 30% compared to pre-administration levels. The nadir of platelet 
depression in most patients is found between 12 and 16 weeks following administration of the 
radiopharmaceutical. White blood cells are usually depressed to a varying extent compared to pre-
administration levels (Silberstein, 2005). The treatment response time has been reported as early as 
3 days, but it is most commonly noted in the second or third week after administration, the mean 
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duration of pain reduction is 3 to 6 months (Silberstein, 2005). 
A variety of studies have shown effective palliation of pain following treatment with 89SrCl2 
(palliative response in 65% to 90% of treated patients), with as many as 25% of the patients able to 
discontinue analgesics and 5-20% reporting complete pain relief (Bedi et al., 2014; Sartor et al., 
2013; Silberstein, 2005). 89SrCl2 also reduces the incidence of new bone metastases, but given alone, 
it does not prolong life (Reddy et al., 1986; Silberstein, 2005). Published data suggest that 89Sr has 
been shown to delay the time of appearance of recurrent or new sites of pain requiring therapy. The 
success of 89Sr in providing this benefit probably relates to the long effective half-life of this 
radiopharmaceutical in bone (Eary and Brenner, 2007). 
 
III.C. 90Y-Ethylenediaminetetramethylene phosphonic acid (EDTMP) 
A disadvantage of natural 90Y is its tendency to accumulate in the reticuloendothelial system 
as well as hydroxyapatite surfaces, due to the formation of colloidal hydroxide or yttrium-transferrin 
complexes, followed by transport to the liver (Keeling et al., 1989). Specific deposition of yttrium 
into the skeleton demands its delivery to the target tissue in a chemical form with affinity for 
mineral bone. Compounds with these properties are the phosphonate analogues of 
aminopolycarboxylic acids, in particular, ethylenediaminetetramethylene-phosphonate (EDTMP). 
Biodistribution studies in rats showed a significant skeleton uptake (~50% of injected dose) 
of 90Y-EDTMP, which remained almost unchanged for long periods of time (72 h), and a rapid 
clearance from all soft tissues (Khalid et al., 2014; Rosch et al., 1996). Furthermore, the majority of 
the administered radioactivity was rapidly removed via the urinary system (Keeling et al., 1989). 
Rosch et al. in 1996 reported that the average dose to 1 cm3 of bone metastases per MBq of injected 
90Y-EDTMP was 18 mGy/MBq compared to 1.8 mGy/MBq dose to the red marrow. A rapid 
clearance of 90Y-EDTMP from blood (clearance of 50% injected dose at 2.5 min post 
administration), high concentration of  90Y-EDTMP in bone metastases (maximum at 1.5 hours after 
administration) and negligible retention in the liver were reported in humans (Rosch et al., 1996). 
 
III.D. 117mSn-Diethylenetriaminepentaacetic (DTPA) 
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Optimal blood and soft tissue clearance was measured following intravenous administration 
of 117mSn-DTPA (Gerbail et al., 1997; Lewington, 2005). 117mSn-DTPA mechanism of uptake by 
bone metastases is postulated to rely on the precipitation of stannous oxide on bone surfaces or on 
hydrolysis reactions with hydroxyapatite. Post intravenous administration in humans, the 
radioactivity measured in the bone component accounted for 77.6% of injected activity and showed 
no biological clearance. The remaining 22.4% of administered activity was found to be cleared via 
the urinary system (Gerbail et al., 1997; Lewington, 2005). The clearance rate from blood appeared 
to be considerably slower than other bone agents. However, because of its rather long physical half-
life relative to these biologic parameters, this is not a concern for radiation absorbed dose in target 
sites (Srivastava, 2007). The lesion-to-normal bone ratios ranged from as low as 2 to as high as 9 
and varied from patient to patient and within the same patient (Gerbail et al., 1997). 
A phase I clinical study conducted using 117mSn-DTPA (activity range of 66-573 MBq, 1.78-
15.48 mCi) reported symptom benefit in 9 out of the 10 evaluated patients with no significant 
myelotoxicity (Lewington, 2005). Subsequently, a phase II clinical trial reported a 75% overall pain 
response (range, 60-83%), with complete pain relief in 30% of the patients. The typical response 
time was 19±15 days using activity values of ≤5.29 MBq/kg (0.143 mCi/kg) and 5±3 days in 
patients receiving activities of ≥6.61 MBq/kg (0.178 mCi/kg) (Lewington, 2005). The high ratio of 
bone surface dose to red marrow dose from 117mSn-DTPA, due to the limited range of its moderately 
low-energy conversion electrons emitted during radioactive decay, is one of the most appealing 
features of this radiopharmaceutical for treatment of bone metastases. 
 
III.E. 153Sm-Ethylenediaminetetramethylene phosphonic acid (EDTMP) 
153Sm-EDTMP (Quadramet®, Lantheus Medical Imaging) has a high affinity for bone and 
concentrates in areas of bone turnover. Quadramet® was introduced commercially in 1997 by 
Cytogen Corporation for the relief of pain arising from metastatic bone disease. In patients with 
metastatic lesions, 50% to 65% of the injected radiopharmaceutical will be chemisorbed into the 
bone. Metastatic lesions can accumulate about 5 times more 153Sm-EDTMP than healthy bone tissue 
(Paes and Serafini, 2010). Renal excretion is complete within 8 hours post radiopharmaceutical 
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administration and less than 1% remains in the blood at 5 h post injection. 153Sm-EDTMP given at 
37 MBq/kg (1.0 mCi/kg) leads to pain reduction in 55% to 70% of evaluated patients (Eary et al., 
1993; Silberstein, 2005). An initial clinical study demonstrated dose-limiting myelotoxicity 
following administration of 153Sm-EDTMP, with a maximum tolerated activity of 37 MBq/kg (1 
mCi/kg) (Farhanghi et al., 1992). The distribution of 153Sm-EDTMP is identical to that of other 
bone-seeking radiopharmaceuticals, such as 99mTc-methylene diphosphonte (MDP) (Singh et al., 
1989). As with the other radiopharmaceuticals, pain reduction or relief begins in 1 to 4 weeks post-
treatment and can last for as long as 2 to 17 weeks (Silberstein, 2005, 2000). Mild myelotoxicity 
predictably occurs, with a reduction in leukocyte and platelet counts of approximately 10% to 40%, 
and full recovery in 6 to 8 weeks (Silberstein, 2005).  
 
III.F. 166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonic acid (DOTMP) 
and 166Ho-1-2-propylene di-amino tetra(methylenephosphonic acid) (PDTMP) 
166Ho complexed with DOTMP localizes in the skeleton and clears rapidly and exclusively 
via the kidneys into the urine by virtue of its high overall negative charge. The long range of 166Ho 
β- particles produces higher marrow suppression compared with 153Sm-EDTMP, although the 166Ho-
DOTMP toxicity profile has been reported to be acceptable (Champlin et al., 2004; Volkert and 
Hoffman, 1999). The efficacy and late toxicities observed indicated that even at high administered 
activities, the marrow was not the dose-limiting organ, but rather the kidneys and urinary bladder 
(Breitz et al., 2006). Skeletal uptake of 166Ho-DOTMP varied from 19% to 39% of the injected 
activity (mean skeletal uptake of 28%, n=12 patients, 2 administrations of 1.1 GBq (30mCi) of 
166Ho-DOTMP 1 week apart) (Breitz et al., 2006). An alternative to 166Ho-DOTMP is 166Ho-PDTMP 
(Zolghadri et al., 2013). Following intravenous injection into rats (26 MBq), 166Ho-PDTMP is 
completely washed out from the circulation within 48h post-administration. It is rapidly taken up by 
the bones over 2h after administration, and it is retained in bone tissue up to 24h post-
administration. This compound has almost no liver, kidney or spleen accumulation, which is a major 
advantage from the dosimetric perspective of a therapeutic radiopharmaceutical (Zolghadri et al., 
2013). 
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III.F. 170Tm-Ethylenediaminetetramethylene phosphonic acid (EDTMP) 
Following intravenous injection in healthy rats, 170Tm-EDTMP displays a good skeletal 
accumulation (50-55% of injected activity), with no significant uptake in others vital organs and 
rapid urinary excretion of 37% at 3 hours after injection (Das et al., 2009). No clinical data has been 
reported to date for this radiopharmaceutical. Administration of 170Tm-EDTMP along with short-
lived radiopharmaceuticals like 153Sm or 177Lu (also labelled with EDTMP complexes) could give 
immediate as well as long-term pain relief, thereby combining the merits of both short- and long-
lived radionuclides for bone pain palliation (Das et al., 2009). 
 
III.G. 177Lu-Ethylenediaminetetramethylene phosphonic acid (EDTMP) and 177Lu-1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonate (DOTMP) 
Pre-clinical trials in dogs showed that 177Lu-EDTMP is taken up almost exclusively by the 
skeletal system (>70%), with minimal activity accumulation in other organs (Bahrami-samani et al., 
2012; Máthé et al., 2010; Saeed et al., 2012). Clinical trials with 177Lu-EDTMP showed an obvious 
reduction in the pain scores at 2 to 6 weeks after the radiopharmaceutical administration. The rate of 
complete response in the bone pain palliation was between 55% and 80%. This study demonstrated 
that an administered activity of 1295 MBq (35 mCi) was sufficient for bone pain palliation therapy 
and administered activities as high as 2590 MBq (70 mCi) were well tolerated (Shinto et al., 2014; 
Yuan et al., 2013). Taken together the data indicated that the 177Lu-EDTMP had an adequate bone 
uptake, rapid urinary excretion and prolonged retention in the bone tissue. Hematologic toxicity was 
mild and transient (Agarwal et al., 2014). All these characteristics along with its optimum physical 
and chemical properties render 177Lu-EDTMP a promising therapeutic agent for pain palliation 
(Saeed et al., 2012). Moreover, Agarwal et al. in 2014 reported in a phase II clinical study (n=44) an 
overall response rate of 86% after intravenous administration of 177Lu-EDTMP, with a median time 
of response of 8 days and median duration of 3 months (Agarwal et al., 2014).   
177Lu-DOTMP pre-clinical trials showed a skeletal uptake of 16% of injected dose in healthy 
mice, with the remaining activity being excreted almost entirely via the urinary system. This 
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radiopharmaceutical causes less myelosuppression than an equivalent dose of 153Sm-EDTMP (Bryan 
et al., 2009).  
A comparative study between 177Lu-EDTMP and 177Lu-DOTMP showed that 177Lu-EDTMP 
has marginally higher skeletal accumulation in comparison to that of 177Lu-DOTMP, while the latter 
has slightly faster blood clearance along with lower retention in liver and kidneys in animal models 
(Chakraborty et al., 2008). Furthermore, another comparative study investigating EDTMP 
complexes labelled with different radionuclides (177Lu, 166Ho, 90Y and 153Sm) showed a skeletal 
uptake of 70% for 177Lu-EDTMP, followed by 153Sm-EDTMP (58%), 90Y-EDTMP (45%) and 
166Ho-EDTMP (36%). All these radiopharmaceuticals showed good renal and rapid blood clearance 
(Sohaib et al., 2007). These data suggest that replacing the radionuclides 153Sm and 90Y with 177Lu in 
the EDTMP complex would improve the potential for cell death in the target tissue, while reducing 
the bone marrow toxicity due to the shorter tissue penetration range of 177Lu β- particles in 
comparison with those of 153Sm and 89Sr β- particles.  
 
III.H. 186/188Re-Hydroxyethylidene-diphosphonate (HEDP) 
Following administration of 186Re-HEDP, around 70% of the radioactivity is excreted in the 
urine over 72 hours (Rijk et al., 1992; Silberstein, 2005). Similar to 89Sr-EDTMP, this 
radiopharmaceutical is retained longer in the reactive bone around the lesion than in normal bone. In 
initial clinical trials, approximately 1221 MBq (33 mCi) of 186Re-HEDP was administered as a 
single intravenous injection to 20 patients diagnosed with prostate cancer with osseous metastases. 
Pain relief was reported in 80% of patients with only mild and transient marrow toxicity. Later, with 
administered activities of 186Re-HEDP ranging between 1110 to 2590 MBq (30 to 70 mCi), a 
therapeutic response has been reported in about 55% to 80% of the cases, and pain relief occurred 
within 1 to 3 weeks (Sartor, 2004; Silberstein, 2005). On another clinical trial, administration of 
186Re-HEDP resulted in pain relief in 77% of the treated patients and around 20% of the patients 
receiving 186Re-HEDP reported to be pain free (K. Liepe et al., 2003; Liepe et al., 2005). Overall, 
most clinical studies using 186Re-HEDP to relieve pain from bone metastases have reported rates of 
pain relief up to 87% (Han et al., 2002). The mean duration of pain relief after the first dosage of 
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186Re-HEDP was 6 weeks (Goyal and Antonarakis, 2012).  
The maximum tolerated administered activity of 186Re-HEDP in patients with metastatic 
cancer was found to be 2405 MBq (65 mCi) with thrombocytopenia as the dose-limiting toxicity 
(De Klerk et al., 1980). 188Re-HEDP has similar biodistribution and radiation dosimetry 
characteristics as 186Re-HEDP and appears to result in similar benefits and toxicities in patients with 
skeletal metastases (Maxon et al., 1998).  
The pain relief data reported following administration of 186Re-HEDP compare favorably with 
the reported pain relief of 67% for 188Re-HEDP. Moreover, 16% of patients treated with 188Re-
HEDP and 13% treated with 186Re-HEDP were able to discontinue their analgesics and were pain-
free (Liepe, 2005). Treatments with 186Re-HEDP have a mean duration of response of seven weeks. 
The only toxicity reported was mild and reversible thrombocytopenia (Liepe, 2005). 
 
III.I. 223Ra-Chloride 
223Ra-Choride (223RaCl2) concentrates in bone as a consequence of being calcium-mimetic 
and its peak skeletal uptake occurs within 1 hour of injection, with no subsequent redistribution. Its 
blood clearance is rapid after intravenous administration and the total skeletal uptake is estimated to 
range between 40% and 60% of the administered activity (Goyal and Antonarakis, 2012). Unlike 
most bone-seeking radionuclides, excretion is predominantly via gastrointestinal tract, with less than 
10% renal clearance (Lewington, 2005).  
In clinical reports, this radiopharmaceutical had a pain response up to 71% and the pain-
relieving effect was present after 2 weeks, presenting a mean duration in responders of 
approximately 50 days. Data from these studies showed that there was no evidence of long-term 
toxicity during the 2-year follow-up and administered activities of at least 50 kBq/kg had a 
significant positive effect in bone alkaline phosphatase (ALP), prostate-specific antigen (PSA) 
levels, pain reduction and overall survival (El-Amm et al., 2013; Harrison et al., 2013; Nilsson 
et al., 2012). In general, 223RaCl2 was well tolerated, and no dose-limiting hemotoxicity was 
observed (Harrison et al., 2013). Some reversible mild myelosuppression events were reported, with 
nadirs 2 to 4 weeks after injection and complete recovery during 8 weeks post radiopharmaceutical 
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administration. The neutrophils were more frequently affected than the platelets, whereas for β- 
emitters thrombocytopenia is often the clinically important toxicity. The most common forms of 
adverse event were transient diarrhea, fatigue, nausea and vomiting (Nilsson et al., 2005a). In 
clinical studies, 223RaCl2 has demonstrated a highly significant improvement on patient overall 
survival, with mild side effects owing to its localized tissue penetration (2-10 cells). Overall, 
223RaCl2 has demonstrated highly favorable toxicity profile, though long-term toxicity data are not 
available (Sullivan et al., 2013). 
223RaCl2 (XofigoTM, Bayer Pharmaceuticals) is the first alpha particle-emitting 
radiopharmaceutical approved for routine clinical use by the FDA (Harrison et al., 2013). To date, 
223Ra-dicloride is the only radiopharmaceutical identified for treatment of palliative bone 
metastasis with shown ability to increase patients’ life-expectancy (Harrison et al., 2013; 
Nilsson et al., 2013a).  
 
IV. THE IDEAL RADIOPHARMACEUTICAL FOR BONE PAIN PALLIATION 
Over the years, efforts have been undertaken to identify radionuclides with improved physical 
properties for use in palliative care of metastatic bone pain, as well as, to develop better bone-
seeking agents to be used for radiolabelling with promising radionuclides. Based on the literature 
review conducted here, it is proposed a flowchart to support selection of the most suitable 
radionuclide and radiopharmaceutical based on the characteristics of an ideal radiopharmaceutical for 
bone pain palliation (Figure 1). 
 
< Insert Figure 1 around here > 
 
 Treatment success depends on matching the physiologic characteristics of the target tissue to 
a specific pharmaceutical carrier and optimal radionuclide. Interestingly, when comparing the 
clinical response across the available data, there appears to be no substantial difference in 
palliative efficacy among radiopharmaceuticals. Although the clinical outcomes of the palliative 
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treatment of bone metastases using radiopharmaceuticals can vary with the radionuclide used, in 
general, it can be stated that the overall benefit from all these treatments is around 75% and that 
about 25% of the patients have complete response. Despite the similar overall benefit reported 
across different radiopharmaceuticals, the measured uptake by the bone tissue varies as much as 
between 16% and 85%. Because most bone seeking radiopharmaceuticals act as calcium-mimetic 
agents, and thus localize in bone crystal rather in or on cancer cells, it may be reasonable to 
hypothesize that the disjointed observation of similar pain relief across radiopharmaceuticals versus 
varying uptake values in bone could be due to DNA damage of cancer cells from decay, with 
subsequent cell death, as well as damage to cells producing pain modulators or analgesic effect by 
targeting nerve terminals in and around the metastasis. Given the overall benefit from metastatic 
bone palliation treatments of around 75% across different radiopharmaceuticals, the choice of the 
radiopharmaceutical most suitable to a given patient may rely on the combination of the physical 
properties of the radionuclide, patient´s life expectancy and patient’s overall clinical state at the 
time of the therapeutic, including myelosupression response.  
The radionuclide properties play one of the most important roles to achieve effective 
accumulated dose per unit time. In this regard, a shorter half-life is an advantage to achieve large 
doses per unit time (Unak, 2002). Different half-lives imply different dose rates, if the surviving cells 
in the irradiated volume are continuously proliferating (Guerra Liberal et al., 2014; Neves et al., 
2005). For example, delivery of 90% of the total dose of radiation requires approximately 3.5 
half-lives of decay (Sartor, 2004), which will correspond to a time interval of approximately 64 
weeks for 170Tm, 25 weeks for 89Sr and 1 week for 153Sm (Sartor, 2004). Data from clinical studies 
has shown that the duration of treatment response is variable and is usually reported to range 
between 2 and 6 months. Moreover, typically, there is a delay in treatment response that can vary 
between 1 and 3 weeks after injection. This delay is shorter using shorter-lived radionuclides. Taken 
together, this information can be particularly valuable when defining which radiopharmaceutical to 
use for treatment of patients with short life expectancies (<3 months), given that longer time periods 
required to deliver 90% of the radiation dose (i.e. radionuclides with longer half-lives) may be 
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disadvantageous for patients with short life expectancy (Krishnan et al., 2014). Consequently, it is 
possible to rank the radionuclides available in two major groups: 1) useful for treatment of short-
life expectancy patients, namely, 32P, 90Y, 117mSn, 153Sm, 166Ho, 177Lu, 186Re, 188Re and 223Ra; and 2) 
useful for treatment of long-life expectancy patients, namely, 32P, 89Sr, 90Y, 117mSn, 153Sm, 166Ho, 
177Lu, 170Tm, 186Re, 188Re and 223Ra. 
A major challenge associated with the palliative treatment of bone pain using selective 
radiopharmaceuticals is to deliver the adequate dose of ionizing radiation to the bone lesion while 
minimizing the dose to healthy bone sites and adjacent tissues. Consequently, the emitted particles 
should have an energy and tissue penetration range compatible with the volume of the lesion to be 
irradiated (Chakraborty et al., 2008; Daha et al., 2010; Wang et al., 2011). Zalutsky et al. in 2000 
compared the penetration ranges of different radioactive particles and reported that 90Y β- particles 
(E(max)=2.3 MeV) had the range of 215 cells size, 131I β- particles (E(max)=0.8 MeV) had a range of 40 
cells size and 211At α particles (E(max)=6.8 MeV) had a range of only 3 cells size (Zalutsky and 
Vaidyanathan, 2000). Therefore, owing to their short penetration range, systemic tumor-targeted 
radiotherapy with Auger electrons or alpha particles often yields lower toxicity to the bone marrow 
in comparison to β- particles (Tavares and Tavares, 2010). Hence, radionuclides emitting Auger 
electrons or alpha particles are appropriate for single cell killing or micro-metastasis, while 
radionuclides emitting β- particles seem better placed to destroy large size tumors. Bernhardt et al. 
in 2001 reported that as the energy of electrons increased, absorbed dose rate decreased in small 
tumors (Bernhardt et al., 2001; Uusija et al., 2006). This study highlights the importance of 
particle energy in target-tumor radiotherapy. This together with the penetration range of 
different particles helps ranking the radionuclides available in two major groups: 1) useful for 
treatment of small tumors and micro-metastases, namely, 117mSn, 177Lu and 223Ra; and 2) useful for 
treatment of medium to large tumors, namely, 32P, 89Sr, 90Y, 153Sm, 166Ho, 170Tm, 186Re and 188Re. In 
agreement with this ranking perspective are previous studies demonstrating that 177Lu is found to be 
effective in localizing cytotoxic radiation in relatively small areas and proficient in destroying small 
tumors, as well as, metastatic lesions (typically less than 3 mm diameter) with less damage to 
surrounding normal tissue (Dash et al., 2015).   
		 23	
Hematologic toxicity has been the primary adverse effect associated with 
radiopharmaceutical administration reported in the studies that assessed this outcome. 
Thrombocytopenia was reported as an adverse effect in 30-50% of patients treated with 
radiopharmaceutical and was typically mild. Neutropenia was a less commonly reported side 
effect when radiopharmaceuticals were used alone, but was more common in reports of 
radiopharmaceuticals combined with chemotherapy and in treatments using 223Ra (Bauman et al., 
2005). The major dose-limiting factor for radionuclide therapy is bone marrow toxicity, which 
results in a reduction in peripheral blood count, especially count of platelets. Consequently, treatment 
of bone pain palliation with 32P would be suboptimal owing to the substantial bone marrow toxicity 
of this β- emitter, most likely due to the high tissue penetration range of the emitted radioactive 
particles. In this regard, using radiopharmaceuticals with mild side effects such as, 177Lu-DOTMP, 
177Lu-EDTMP or 117mSn-DTPA, would be preferable than radiopharmaceuticals reported to yield 
significant side effects, such as 89SrCl2 or 32P-orthophosphate, in particular, when multi-treatment 
regimens are foreseen for a given patient with high life-expectancy.      
It is also important that the radionuclide to be used for palliative treatment of bone metastases 
allows for in vivo imaging, in order to assist with the determination of the suitable administered 
activity to be used and to facilitate treatment response monitoring over time, which is particularly 
valuable for patients with long term life-expectancy (Henriksen et al., 2003; Pandit-Taskar et al., 
2014). To this regard, the Auger electron emitter 117mSn has the highest percentage of gamma ray 
emission, followed by 153Sm, 188Re and 177Lu.  
Typically, radiopharmaceuticals must also meet several specifications in order to fulfill 
clinical requirements, including high specific activity, high radiochemical and radionuclide purity, 
and high radiochemical yield. No carrier added radionuclides are ideal to obtain high specific activity 
radiopharmaceuticals. This will ensure that a larger amount of radioactive tagged carrier molecules is 
delivered to the tumor, thus improving the delivery of radiation absorbed dose per unit of injected 
activity. Notwithstanding, while targeted radionuclide therapy is primarily based on selecting 
appropriate radiopharmaceuticals and targeting mechanisms, the number of target sites (receptors, 
		 24	
cells, etc.) available for radiopharmaceutical targeting dictates the specific activity of the 
radionuclide that is suitable for a particular application. Trabecular bone is considered a large 
capacity site and does not require a radionuclide with very high specific activity. For this reason, the 
need for a radionuclide with high specific activity for treatment of bone metastases is less pressing 
than other receptor based therapies. Under this premise, medium-low specific activity radionuclides 
can generally be used for palliative treatment of bone metastases (Dash et al., 2015). 
In addition to the radionuclide and radiopharmaceutical properties discussed above, other 
factors should be taken into consideration while searching for the ideal radiopharmaceutical for 
palliative treatment of bone metastases. Inevitably, one would have to consider the costs of a given 
therapeutic and the logistics associated with a particular radionuclide production. Radionuclides 
produced via generator or presenting longer half-lives would represent a less cumbersome approach 
in terms of production and worldwide distribution than radionuclides with short half-lives and 
complicated production routes. Nonetheless, the benefit to the patient needs to be factored here by 
considering the patient life-expectancy and hematologic profile at the time of the therapy.    
 
V. CONCLUDING REMARKS AND FUTURE PROSPECTS 
Despite the increasing availability of radionuclides for palliative treatment of bone metastases 
(Das et al., 2009; Goyal and Antonarakis, 2012), the choice of which therapeutic agent to use is far 
from unanimous and no standardization or guideline exists to assist with this choice. 89SrCl2 and 
153Sm-EDTMP, two commercially available radiopharmaceuticals, still account for the bulk of bone 
pain palliation radiotherapy (Das and Pillai, 2013). Remarkably, the range of physical properties of 
the radionuclides available for bone pain palliation is wide, with half-lives ranging from less than a 
day (188Re) to 128.4 days (170Tm) and mean particles energy as low as 0.13 MeV (117mSn) and as high 
as 5.716 MeV (223Ra). Thus, the time might be right for a careful rationalization exercise to assist 
with the process of selecting the best agent for a given therapeutic application within the context of 
bone pain palliation.  
While a myriad of factors contribute to the success of palliative treatment of bone metastasis 
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using radiopharmaceuticals, the patients’ life expectancy and overall clinical status, including 
hematologic profile can be defining initial criteria for subsequent selection of which radionuclide 
and radiopharmaceutical to use. Given that the reported therapeutic effects of various 
radiopharmaceuticals has been similar, we propose the use of patients’ life expectancy together with 
the radionuclide half-life as the first line of approach for selection of the ideal radiopharmaceutical 
for a given patient. Then the size of tumor may be factored in together with the radionuclide tissue 
penetration range. Ability to image patients and follow treatment response can be another important 
feature, in particular, in patients with long term life expectancy. Cost-effectiveness of a given 
radiopharmaceutical production and distribution can then further narrow the choice. Using this 
strategy, 177Lu- and 188Re-labeled radiopharmaceuticals appear to be the most favorable for 
treatment of small and medium/large size tumors, respectively. Their cost-effective and convenient 
availability would be advantageous for underpinning the success of using 177Lu- and 188Re-labeled 
radiopharmaceuticals for in vivo targeted therapy of bone metastases. Unfortunately, current wide 
access and clinical use of these radiopharmaceuticals is not yet a reality, and a solution to this and 
other unresolved issues can be time consuming and hinder the use of these radiopharmaceuticals in 
the near future.   
In conclusion, several aspects need to be considered when choosing the radiopharmaceutical 
to use for target-tumor radiotherapy. This should go beyond the inevitable analysis of costs and 
logistics, and should include an analysis of the radionuclide physical properties, as well as, size of 
the lesions to be treated, patient’s clinical condition and life expectancy, in order to optimize the 
therapeutic efficacy. In this paper, we proposed an approach to assist with the rational selection of 
the ideal radiopharmaceutical for palliative treatment of bone metastases for a given patient, based 
on previously published literature for different radionuclides and radiopharmaceuticals.  
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FIGURE CAPTIONS 
 
Figure 1. Selection of the radionuclide/radiopharmaceutical based on the physical characteristics of the 
radionuclide and patient’s life expectancy. 177Lu and 188Re-labeled radiopharmaceuticals appear to be the 
most suitable choices for treatment of small and medium/large size bone lesions, respectively.  
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TABLE CAPTIONS 
 
TABLE I: Summary of main physical properties of different radionuclides in clinical use or under research 
for palliative treatment of bone metastases.  
 
TABLE II. Summary of the key clinical outcomes of different radiopharmaceuticals currently used in the 
clinical setting or under research for palliative treatment of bone metastases. 
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Figure 1 
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TABLES 
Table I: Summary of main physical properties of different radionuclides in clinical use or under research for palliative treatment of bone metastases.  
Radionuclide Emission type 
E mean 
(MeV) (%) 
Eγ 
(keV) 
(%) 
T1/2  
(days) 
Tissue 
penetration 
 max. (mm) 
 
Main production mode (impurities) 
Production and 
logistics cost References  
32P β
- 0.6955  (100) - 14.3
 8.0 
31P(n,γ) 32P (None) 
32S(n,p) 32P (33P, 35S) 
34S(d,α) 32P (None) 
High 
Cost-effective 
High 
(Bé et al., 2008; Lewington, 2005; Vimalnath et al., 2013; 
Volkert and Hoffman, 1999) 
89Sr β
- 0.5846 (99.99) 
909 
(0.1) 50.5
 6.7 
88Sr(n,γ) 89Sr  (85Sr, 90Sr)  
Fission Product (90Sr) 
87Sr(t,p) 89Sr (None) 
86Kr(α,nγ) 89Sr (None) 
High 
High 
High 
High 
(Bé et al., 2008; Lewington, 2005; Volkert and Hoffman, 1999) 
90Y β
- 0.927    (99.98) - 2.67
 11 
90Sr(β)  90Y (None) 
89Y(n,γ) 90Y  (91Y)  
High 
Cost-effective 
(Bé et al., 2008; Volkert and Hoffman, 1999) 
117mSn Auger 
0.1268    
(64.8) 
159 
(86) 13.6
 0.3 
116Sn(n,γ) 117mSn (None) 
117Sn(n,n’) 117mSn (None) 
High 
High 
(Bé et al., 2008; Lewington, 2005; Maslov et al., 2011; Volkert 
and Hoffman, 1999) 
153Sm β
- 0.2253    (48.2) 
103 
(28) 1.93
 3.4 
152Sm(n,γ) 152Sm (None) 
150Nd(n,α) 153Sm (None) 
High 
High 
(Bé et al., 2008; Lewington, 2005; Volkert and Hoffman, 1999) 
166Ho β
- 0.6511    (50.5) 81 (6.4) 1.12
 8.6 
165Ho(d,p) 166Ho (166mHo) 
165Ho(n,γ)(E=thermal) 166Ho (None) 
166Dy - decay chain (None) 
High 
Cost-effective 
High 
(Bé et al., 2008; Knapp, 2001; Volkert and Hoffman, 1999) 
170Tm β
- 0.3231    (81.6) 84 (3.3) 128.4
 5 
169Tm(n,γ) 170Tm (None) 
170Er(p,n) 170Tm (168Tm) 
Cost-effective 
High 
(Bé et al., 2008; Das et al., 2009) 
177Lu β
- 0.1494    (79.3) 
208 
(10.4) 6.2
 1.8 
176Lu(n,γ) 177Lu (176mLu)  
176Yb(n,γ) 177Yb  à177Lu 
High 
Cost-effective 
(Bé et al., 2008; Knapp, 2001; Pillai et al., 2003; Volkert and 
Hoffman, 1999) 
186Re β
- 0.3596    (70.9) 137 (9) 3.8
 4.7 
185Re(n,γ) 186Re (186mRe, 188Re) 
186W(n,p) 186Re (None) 
Cost-effective 
Cost-effective 
(Bé et al., 2008; Lewington, 2005; Volkert and Hoffman, 1999) 
188Re β
- 0.7304    (71.1) 
155 
(15) 0.7
 10.4 188We(n,n) 188Re (None) Cost-effective (Argyrou et al., 2013a, 2013c; Bé et al., 2008; Lewington, 2005) 
223Ra α 
5.71581  
(45.6) 
154 
(5.6) 11.4
 0.1 
235U - decay chain (None) 
227Ac/227Th  Generator (None) 
High 
Cost-effective 
(Bé et al., 2008; Henriksen et al., 2003; Lewington, 2005) 
Legend: T1/2 (days) – radioisotope half-life in days; E (MeV) (%) – particle energy and respective decay abundance shown in parentheses; Eγ (keV) (%) – gamma ray energy and respective abundance in total energy 
emission shown in parentheses; Tissue penetration range (mm) – maximum tissue penetration in soft tissue shown in millimeters. 
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TABLE II. Summary of the key clinical outcomes of different radiopharmaceuticals currently used in the clinical setting or under research for palliative 
treatment of bone metastases. 
Radiopharmaceuticals %bone uptake 
Main 
elimination 
route 
Response 
to 
therapy 
(%) 
Duration of 
therapeutic 
response 
(months) 
Hematologic effects 
(% patients with 
toxicity grade >2) 
Side effects 
rating 
Regulatory 
status References 
WBC Platelets 
32P-orthophosphate 85 Urinary 50-87 2-7 14 34 Significant 
Approved and 
commercially 
available in 
undeveloped 
countries 
(Silberstein, 
2005) 
89SrCl2 55 Urinary 65-90 3-6 37 61 Significant 
Approved and 
commercially 
available 
(Fosså et al., 
1992; 
Silberstein, 
2005; 
Srivastava, 
2004) 
90Y-EDTMP 45-50 Urinary -- -- -- -- -- -- (Khalid et al., 2014) 
117mSn-DTPA 77 Urinary 60-83 4-5 11 0 Mild In clinical trails 
(Srivastava, 
2004) 
153Sm-EDTMP 65 Urinary 55-83 2-3 15 25 Moderate 
Approved and 
commercially 
available 
(Serafini et 
al., 1998; 
Srivastava, 
2004) 
166Ho-DOTMP 16-54 Urinary NE NE -- -- Moderate In clinical trails 
(Champlin et 
al., 2004; 
Ueno et al., 
2009) 
170Tm-EDTMP 50-55 Urinary -- -- -- -- -- -- (Das et al., 2009) 
177Lu-DOTMP 70 Urinary NE NE -- -- Mild -- (Chakraborty 
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et al., 2008) 
177Lu-EDTMP 54-80 Urinary 55-86 3 14 11 Mild In clinical trails 
(Agarwal et 
al., 2014; 
Yuan et al., 
2013) 
186Re-HEDP 55 Urinary 55-85 2-4 17 25 Moderate 
Approved and 
commercially 
available in 
Europe 
(Han et al., 
2002; 
Srivastava, 
2004) 
188Re-HEDP 30 Urinary 64-77 3-6 20 25 Moderate In clinical trails  
(K. Liepe et 
al., 2003) 
223RaCl2 41 Intestinal 58-75 2-3 4 2 Mild 
Approved and 
commercially 
available 
(Harrison et 
al., 2013; 
Nilsson et 
al., 2012; 
Sartor et al., 
2013) 
Legend: NE – not established; WBC – white blood cells. Note: Data for 90Y-EDTMP and 170Tm-EDTMP is preclinical.  
